Founded in 2016, MEGAROBO is a science and technology company specializing in providing advanced production tools for life sciences, new drug discovery, clinical diagnostics, applied chemistry and advanced manufacturing industries. MEGAROBO is dedicated to leveraging robotic automation and AI technologies to empower innovation breakthroughs and digital transformation, to engineer a more efficient, healthier and better world.

MEGAROBO provides innovative intelligent automation products and solutions of high quality for the life sciences industry, covering R&D, production and detection. With the research capabilities of MegaLab, the self-developed intelligent biological laboratory, MEGAROBO provides high-value productivity tools and services, accelerating the intelligent automation revolution in new drug discovery, cell and gene therapy, organoids and synthetic biology, ultimately improving human health.

MEGAROBO values independent development and technological innovation, and assembles over 1000 interdisciplinary professionals, with 60% dedicated to R&D. MEGAROBO holds 320 patents, demonstrating our expertise in multiple core technologies with global competitive capabilities. The global headquarters is in Singapore. MEGAROBO owns sites in Beijing, Shanghai, Shenzhen, Suzhou and Hong Kong, and globalised in the United States, the United Kingdom and Japan.

MEGAROBO has closed its Series C financing round. And MEGAROBO got long-term support from key investors including WuXi AppTec, Bosch, Sino Biological, Goldman Sachs Asset Management, Asia Investment Capital, GGV Capital, Sinovation Ventures, Joy Capital, Matrix Partners China, and Pavilion Capital.